CA Patent

CA3176436A1 — Bispecific antibodies against cd3 and cd20

Assigned to Genmab AS · Expires 2021-11-11 · 5y expired

What this patent protects

The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).

USPTO Abstract

The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).

Drugs covered by this patent

Patent Metadata

Patent number
CA3176436A1
Jurisdiction
CA
Classification
—
Expires
2021-11-11
Drug substance claim
No
Drug product claim
No
Assignee
Genmab AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.